Alkem Laboratories マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Vikas Gupta

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.2yrs
CEOの所有権	n/a
経営陣の平均在職期間	1.2yrs
取締役会の平均在任期間	7.2yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Vikas Gupta

1.2yrs

在職期間

Dr. Vikas Gupta is Chief Executive Officer of Alkem Laboratories Limited from September 22, 2023. He has experience in Pharmaceutical Sector and brings with him deep experience across therapeutic areas inc...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Basudeo Singh	Executive Chairman	51.3yrs	₹200.60m	13.31% ₹ 87.8b
Sarvesh Singh	VP of Sales & Marketing and Executive Director	no data	₹44.50m	0% ₹ 0
Sandeep Singh	MD & Executive Director	1.2yrs	₹81.50m	0.0065% ₹ 43.1m
Mritunjay Singh	Executive Director	no data	₹104.30m	8.58% ₹ 56.6b
Srinivas Singh	Executive Director	2.2yrs	₹96.60m	0.086% ₹ 566.4m
Madhurima Singh	Executive Director	no data	₹104.10m	8.77% ₹ 57.8b
Vikas Gupta	Chief Executive Officer	1.2yrs	データなし	データなし
Akhilesh Sharma	President & Chief Medical Officer	no data	データなし	データなし
Kaustav Banerjee	President & Head Medtech Business	less than a year	データなし	データなし
Rajorshi Ganguli	President & Global HR Head	no data	データなし	データなし
Nitin Agrawal	CFO & President of Finance	less than a year	データなし	データなし
Satish Singh	Head of Operations	no data	データなし	0.060% ₹ 396.7m

1.2yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: 539523の経営陣は経験豊富とはみなされません ( 1.2年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Basudeo Singh	Executive Chairman	51.3yrs	₹200.60m	13.31% ₹ 87.8b
Sarvesh Singh	VP of Sales & Marketing and Executive Director	5yrs	₹44.50m	0% ₹ 0
Sandeep Singh	MD & Executive Director	11.3yrs	₹81.50m	0.0065% ₹ 43.1m
Mritunjay Singh	Executive Director	16yrs	₹104.30m	8.58% ₹ 56.6b
Srinivas Singh	Executive Director	2.2yrs	₹96.60m	0.086% ₹ 566.4m
Madhurima Singh	Executive Director	2.9yrs	₹104.10m	8.77% ₹ 57.8b
Arun Purwar	Independent Director	9.7yrs	₹3.30m	データなし
Sudha Ravi	Independent Director	9.4yrs	₹3.10m	データなし
Sangeeta Singh	Independent Director	9.4yrs	₹3.00m	データなし
Narendra Aneja	Independent Director	4.7yrs	₹3.20m	データなし
Rajeev Kher	Independent Director	less than a year	データなし	データなし
Sujjain Talwar	Independent Director	2.3yrs	₹2.70m	データなし

7.2yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: 539523の取締役会は経験豊富であると考えられます ( 7.2年の平均在任期間)。

Alkem Laboratories マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Alkem Laboratories Limited Announces Retirement of Yogesh Kaushal as Senior Management Personnel

Alkem Laboratories Limited Approves Appointment of Rajeev Kher as an Independent Director

Alkem Laboratories Limited Announces Change in Management

Less than half of directors are independent

Alkem Laboratories Limited, Annual General Meeting, Aug 30, 2024

Alkem Laboratories Limited Announces CFO Changes

Recent updates

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alkem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Alkem Laboratories Limited Announces Retirement of Yogesh Kaushal as Senior Management Personnel

Alkem Laboratories Limited Approves Appointment of Rajeev Kher as an Independent Director

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

KKR, TPG Capital, Apax Partners and Other PE Firms Reportedly Eye Purchase of Sahajanand Medical Technologies

KKR, TPG Capital, Apax Partners and Other PE Firms Reportedly Eye Purchase of Sahajanand Medical Technologies

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings: EPS and revenues miss analyst expectations

Alkem Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024

Alkem Laboratories Limited Announces Change in Management

Less than half of directors are independent

Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection

Alkem Laboratories Limited, Annual General Meeting, Aug 30, 2024

Final dividend of ₹5.00 announced

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024

Full year 2024 earnings released: EPS: ₹150 (vs ₹82.31 in FY 2023)

Alkem Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Price target increased by 15% to ₹4,936

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Consensus forecasts updated

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

High number of new directors

U.S. Food and Drug Administration Conducts Pre-Approval Inspection At Alkem Laboratories Limited Manufacturing Facility Located At St. Louis, Usa

Alkem Laboratories Limited Appoints Srinivas Singh as (Executive) Additional Director and Whole Time Director

Alkem Laboratories Limited Announces Retirement of Balmiki Prasad Singh as Executive Director

Consensus EPS estimates fall by 11%

Price target decreased to ₹3,357

Alkem Laboratories Limited Appoints Sujjain Talwar as an Additional Director, Designated as an Independent Director on the Board of Directors

Upcoming dividend of ₹4.00 per share

Alkem Laboratories Limited to Report Q1, 2023 Results on Aug 05, 2022

Less than half of directors are independent

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Announces Resignation of Ranjal Laxmana Shenoy as Non- Executive Independent Director

Price target decreased to ₹3,624

Alkem Laboratories Limited Proposes Final Dividend for Financial Year Ended 31 March, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹90m worth of stock

マネジメント基準チェック /14